AVITA Medical, Inc. Australian S.E.

AVH

AU000000AVH4

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 04:13:02 02/07/2024 BST			5-day change	1st Jan Change
2.39 ^AUD	-2.05%		-3.24%	-44.29%

07-01	Avita Medical Names Chief Legal, Compliance Officer	MT
07-01	AVITA Medical, Inc. Announces Executive Changes	CI

AVITA Medical, Inc. Announces Resignation of Kathy McGee as Chief Operating Officer

January 19, 2023 at 09:28 pm

AVITA Medical, Inc. announced that Chief Operating Officer, Kathy McGee, will be leaving the organization. The Company does not plan to replace the role of Chief Operating Officer.

Latest news about AVITA Medical, Inc.

Avita Medical Names Chief Legal, Compliance Officer	07-01	MT
AVITA Medical, Inc. Announces Executive Changes	07-01	CI
AVITA Medical, Inc.(NasdaqCM:RCEL) dropped from S&P Biotechnology Select Industry Index	06-23	CI
Avita Medical’s Cell Harvesting Device Treats First US Patient; Shares Rise 5%	06-06	MT
Avita Medical's Recell Go Obtains Approval from US FDA	05-30	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	05-30	MT
Avita Medical Shares Rise After FDA Nod For Recell Go System	05-30	MT
Sector Update: Health Care	05-30	MT
Avita Medical Receives FDA Premarket Approval Supplement for Recell Go System	05-30	MT
AVITA Medical, Inc. Announces FDA Approval of RECELL GO	05-30	CI
Transcript : AVITA Medical, Inc. - Special Call	05-22
Cantor Fitzgerald Trims Price Target on Avita Medical to $21 From $22, Maintains Overweight Rating	05-14	MT
Piper Sandler Downgrades Avita Medical to Neutral From Overweight, Price Target is $9	05-14	MT
Avita Medical Widens Q1 Loss as Sales, Marketing Expense Jumps; Shares Up 10%	05-14	MT
Transcript : AVITA Medical, Inc., Q1 2024 Earnings Call, May 13, 2024	05-13
AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024	05-13	CI
AVITA Medical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target is AU$3.03	04-17	MT
BTIG Research Downgrades Avita Medical to Neutral From Buy	04-11	MT
Avita Medical Lowers Q1 Revenue Guidance on Slower New Account Approvals	04-11	MT
AVITA Medical, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2024 and Full Year Fiscal 2024	04-10	CI
AVITA Medical, Inc.(ASX:AVH) added to S&P/ASX All Ordinaries Index	03-17	CI
AVITA Medical, Inc.(NasdaqCM:RCEL) added to S&P Biotechnology Select Industry Index	03-17	CI
AVITA Medical Submits Additional RECELL GO PMA Supplement Information to US FDA	03-01	MT
Transcript : AVITA Medical, Inc. - Special Call	02-27

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for AVITA Medical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.61 AUD

Average target price

34.91 AUD

Spread / Average Target

+200.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVITA MEDICAL, INC.	-44.29%	206M
MODERNA, INC.	+16.59%	45.51B
IQVIA HOLDINGS INC.	-9.89%	38.52B
LONZA GROUP AG	+38.08%	38.13B
ALNYLAM PHARMACEUTICALS, INC.	+27.12%	30.74B
CELLTRION, INC.	-8.64%	26.03B
ICON PUBLIC LIMITED COMPANY	+11.81%	25.92B
UNITED THERAPEUTICS CORPORATION	+45.08%	14.13B
MEDPACE HOLDINGS, INC.	+32.85%	12.73B
BIO-TECHNE CORPORATION	-7.19%	11.29B

Other Biotechnology & Medical Research

AVITA Medical, Inc. Australian S.E.

Equities

AVH

AU000000AVH4

Biotechnology & Medical Research

AVITA Medical, Inc. Announces Resignation of Kathy McGee as Chief Operating Officer

Latest news about AVITA Medical, Inc.

Chart AVITA Medical, Inc.

Company Profile

Income Statement Evolution

Ratings for AVITA Medical, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research